Continue reading this on our app for a better experience

Open in App
Floating Button
Home Capital Broker's Calls

Venture could see higher earnings in 2020 on buoyant customer sentiment: Maybank

Jeffrey Tan
Jeffrey Tan • 2 min read
Venture could see higher earnings in 2020 on buoyant customer sentiment: Maybank
Venture Corp gets upgraded to "buy" by Maybank Kim Eng Research, with a 7.8% higher target price.
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (Jan 30): As Venture Corp’s major clients are projecting optimism ahead, Maybank Kim Eng Research reckons that the electronic services provider could do better this year.

Maybank believes the company could return to y-o-y earnings growth in 2H20, underpinned by a robust pipeline of key product launches for its customers.

This is on top of consensus’ 2020 revenue forecast for Venture’s customers have been broadly unchanged through 4Q19 as trade tensions subsided, unlike the prior frequent downward revisions as trade tensions escalated.

“This suggests that [Venture’s] customer base is showing signs of operational stabilisation,” Maybank analyst Lai Gene Lih writes in a note dated Jan 29.

“If our thesis plays out, we believe [Venture] may see y-o-y earnings growth in 2H20, assuming 1H:2H seasonality of 46:54,” he adds.

To that end, Maybank has raised its FY20 and FY21 earnings per share forecasts by 6% and 8%, respectively, in line with FactSet consensus.

The brokerage has also increased its target price for Venture to $18.23 from $16.91 previously and maintained its “buy” rating for the stock.

According to Maybank, Venture’s customers have turned more positive this year, owing to their robust product pipeline, pent-up demand from delayed spending and 5G roll-out.

Key customers, such as Agilent, Thermo Fisher and Honeywell, are of the view that the economy has bottomed and are expecting this year to be better than last year, it notes.

This is in contrast to Illumina, which has guided for lower NovaSeq shipments y-o-y in 2020.

The key risk, however, is if the cautious environment persists, caused by trade, US elections and/or general manufacturing-related headwinds, says Maybank.

As at 11.11 am, Venture was up 45 cents or 2.8% at $16.59, with trade volume of 1.2 million shares.

Highlights

Re test Testing QA Spotlight
1000th issue

Re test Testing QA Spotlight

×
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.